OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab Updated Data for Demcizumab and Tarextumab Also Presented CHICAGO and REDWOOD CITY, Calif., June 05, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) …